SCHEMBL8308289

SCHEMBL8308289

C=CCN1C(=O)/C(=C/c2ccc(O)c(OC)c2)SC1=S

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 3/20 0.78
▸ HSD17B3 P37058 1/20 0.71
▸ MEN1 O00255 11/20 0.71
▸ KMT2A Q03164 11/20 0.71
▸ MAPK1 P28482 7/20 0.71
▸ POLB P06746 5/20 0.71
▸ L3MBTL1 Q9Y468 3/20 0.71
▸ EP300 Q09472 1/20 0.67
▸ MAPT P10636 7/20 0.65
▸ ALDH1A1 P00352 6/20 0.65
▸ SMN1; SMN2 Q16637 2/20 0.65
▸ RECQL P46063 3/20 0.63
▸ HPGD P15428 1/20 0.63
▸ LMNA P02545 1/20 0.62
▸ GAA P10253 1/20 0.62
▸ OPRK1 P41145 2/20 0.62
▸ HTT P42858 1/20 0.62
▸ MYC P01106 1/20 0.60
▸ MAX P61244 1/20 0.60
▸ ATM Q13315 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8308291 1.00 PDE4B (0.78) PDE4BHSD17B3MEN1KMT2AMAPK1
SCHEMBL2370857 0.85 PDE4B (0.78) PDE4BMEN1KMT2AMAPK1POLB
SCHEMBL29374482 0.85 PDE4B (0.78) PDE4BMEN1KMT2AMAPK1POLB
SCHEMBL9393527 0.85 PDE4B (0.78) PDE4BMEN1KMT2AMAPK1POLB
SCHEMBL19999083 0.84 MEN1 (0.75) PDE4BMEN1KMT2AMAPK1POLB
SCHEMBL12008489 0.83 FABP4 (0.81) PDE4BMEN1KMT2AMAPK1POLB
SCHEMBL9331154 0.82 PDE4B (0.73) PDE4BHSD17B3MEN1KMT2AMAPK1
SCHEMBL9331160 0.82 PDE4B (0.73) PDE4BHSD17B3MEN1KMT2AMAPK1
SCHEMBL12008732 0.81 CTNNB1 (0.85) PDE4BMEN1KMT2AMAPK1POLB
SCHEMBL8713783 0.81 PDE4B (0.63) PDE4BHSD17B3MEN1KMT2AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0915090-A1 Compounds useful as hypoglycemic agents and for treating Alzheimer's disease ELI LILLY AND COMPANY (US) 1999-05-12 — — EP disclosed
US-5731336-A USING ARYL-SUBSTITUTED RHODAMINES ELI LILLY AND COMPANY (US) 1998-03-24 — — US disclosed
US-5716975-A NONTOXIC RHODANINE DERIVATIVES; ANTIDIABETIC AGENTS, CATHEPSIN D INHIBITORS, B-AMYLOID PROTEIN REDUCTION ELI LILLY AND COMPANY (US) 1998-02-10 — — US disclosed
US-5661168-A ADMINISTERING RHODANINE DERIVATIVES TO CONTROL DIABETES ELI LILLY AND COMPANY (US) 1997-08-26 — — US disclosed
WO-1996022772-A1 METHOD FOR TREATING MULTIPLE SCLEROSIS ELI LILLY AND COMPANY (US) 1996-08-01 — — WO disclosed
EP-0722729-A2 Aryl-substituted rhodanines for treating multiple sclerosis ELI LILLY AND COMPANY (US) 1996-07-24 — — EP disclosed
US-5523314-A RHODANINE DERIVATIVES ELI LILLY AND COMPANY (US) 1996-06-04 — — US disclosed
EP-0587377-A2 Thiazolidinone derivatives as hypoglycemic agents and for treating Alzheimer's disease ELI LILLY AND COMPANY (US) 1994-03-16 — — EP disclosed
Send feedback